$-0.28 EPS Expected for FibroGen, Inc. (FGEN); Omega Healthcare Investors (OHI) Sentiment Is 1.42

February 16, 2018 - By Migdalia James

Omega Healthcare Investors, Inc. is a real estate investment firm. The company has market cap of $5.42 billion. The firm invests in the real estate markets of United States. It has a 31.79 P/E ratio. It invests in healthcare facilities, primarily in long-term healthcare facilities in order to create its portfolio.

Analysts expect FibroGen, Inc. (NASDAQ:FGEN) to report $-0.28 EPS on March, 7.They anticipate $0.26 EPS change or 48.15% from last quarter’s $-0.54 EPS. After having $-0.50 EPS previously, FibroGen, Inc.’s analysts see -44.00% EPS growth. The stock increased 0.62% or $0.35 during the last trading session, reaching $56.8. About 23,479 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has risen 52.86% since February 16, 2017 and is uptrending. It has outperformed by 36.16% the S&P500.

Among 8 analysts covering FibroGen Inc (NASDAQ:FGEN), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. FibroGen Inc had 16 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating by Stifel Nicolaus given on Sunday, September 10. Goldman Sachs downgraded the stock to “Neutral” rating in Friday, July 21 report. Leerink Swann maintained the shares of FGEN in report on Tuesday, August 8 with “Buy” rating. The firm has “Neutral” rating by Credit Suisse given on Thursday, January 21. Citigroup initiated the shares of FGEN in report on Friday, December 4 with “Buy” rating. The stock of FibroGen, Inc. (NASDAQ:FGEN) earned “Buy” rating by Stifel Nicolaus on Wednesday, October 18. The firm earned “Outperform” rating on Thursday, February 11 by Credit Suisse. The stock has “Hold” rating by Lake Street on Wednesday, September 23. Jefferies maintained the stock with “Buy” rating in Tuesday, August 8 report. On Wednesday, July 29 the stock rating was initiated by Citigroup with “Buy”.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $4.66 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: